Brigatinib CAS 1197953-54-0 Bogtinib for Cancer

• Customization: Available
• Grade: Pharmaceutical Grade
• Melting Point: 96-97
• Model NO.: DONGFANG
• Usage: for Cancer Treatment
• Certificate: GMP, ISO 9001
• Suitable for: Adult
• Transport Package: Aluminum Foil Bag/Cartons/Foil Bags
• Specification: 99%
• Trademark: DongFang
• Origin: China
• HS Code: 29335990
• Production Capacity: 5000kg/Month

Product Description

Product Name: Brigatinib
Synonyms: Brigatinib;AP26113 (Brigatinib);Brigatinib, AP26113;5-Chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-2,4-pyrimidinediamine;5-chloro-N4-(2-(dimethylphosphoryl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine;brigatib;140455;Bogtinib (AP26113)
CAS: 1197953-54-0
MF: C29H39ClN7O2P
MW: 584.092421
EINECS: 621-260-7

Melting point: 96-97°C
Boiling point: 781.8±70.0 °C
Density: 1.31±0.1 g/cm3
Storage temp.: Store at RT
Appearance: Off-White Powder

Description:

Brigatinib (AP26113) is a medicine used to treat cancer that suppresses epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Brigatinib is a selective agonist against variations of EGFR as opposed to the wild mutant forms. The drug also illustrates selectivity against the ALK-EML4 fusion gene, which is a fundamental aspect of the modification of susceptible lung parenchyma. Brigatinib is prescribed for patients with specific abnormal genes and when the non-small cell lung cancer (NSCLC) is non-responsive to management with other medications. Brigatinib is classified as a kinase inhibitor, whose mechanism of action entails suppressing the action of abnormal proteins that enhance the multiplication of cancer cells.

Uses:

Brigatinib is a tyrosine kinase receptor (MERTK) inhibitor, which can be combined with epidermal growth factor receptor (EGFR) inhibitors for cancer treatment.